Enhancing Rehabilitation for Veterans With Serious Mental Illness
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-83
SponsorVA Office of Research and Development
About this trial
This study addresses the critical need for innovative therapeutic interventions in Veterans with serious mental illnesses (SMI) receiving care in VA Psychosocial Rehabilitation and Recovery Centers (PRRCs). The vast majority of individuals with SMI suffer from cognitive impairments, leading to chronic functional disability, and impaired outcomes, causing a significant strain on support networks and the VA healthcare system. This study aims to introduce an innovative mental health therapy, Targeted Cognitive Training (TCT), to Veterans struggling with serious mental illnesses (SMI). TCT works to improve basic sensory information processing and, ultimately, clinical, cognitive, and psychosocial functioning. By using EEG biomarkers to identify Veterans with SMI receiving care within VA Psychosocial Rehabilitation and Recovery Centers who are most likely to benefit from this treatment, and by understanding how best to implement this therapy, the investigators hope to enhance care and improve life quality for Veterans with SMI.
Eligibility criteria
Qualifiers
Veterans with SMI (e.g., schizophrenia, schizoaffective disorder, bipolar disorder, PTSD) being treated at PRRCs or co-located rehabilitative services.
Age 18 and 83 years.
Fluency in spoken and written English.
Ability to detect 1000 Hz tones binaurally at a 40-dB sound pressure level.
Disqualifiers
Estimated premorbid IQ below 70, as estimated via the WRAT-4 Reading subtest.
Active substance use other than cannabis within the last 30 days as determined by CPRS review, self- report, or positive urine drug screen (obtained as part of the screening process).
History of significant medical or neurological illness.
Inability to comprehend or provide informed consent.
Trial design
Treatments tested in this trial
- Targeted Cognitive Training
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
VA Office of Research and Development
Lead sponsor
University of California, San Diego
Collaborator
Source ClinicalTrials.gov